tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Qyuns Therapeutics Enhances Governance with New Lead INED Designation

Story Highlights
  • Qyuns Therapeutics appoints Mr. Fung Che Wai, Anthony as lead independent non-executive director.
  • The designation aims to improve corporate governance and board communication.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

The latest announcement is out from Qyuns Therapeutics Co., Ltd. Class H ( (HK:2509) ).

Qyuns Therapeutics Co., Ltd., a joint stock company incorporated in China, has designated Mr. Fung Che Wai, Anthony as the lead independent non-executive director to enhance corporate governance. This move aligns with the amended Corporate Governance Code effective from July 2025, aiming to improve board effectiveness and communication between directors and shareholders.

More about Qyuns Therapeutics Co., Ltd. Class H

Average Trading Volume: 371,734

Technical Sentiment Signal: Strong Buy

For a thorough assessment of 2509 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1